INCYTE CORP: insider trades · United States · SEC (Form 4)

About INCYTE CORP

Incyte Corp. (NASDAQ: INCY) is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for areas of high unmet medical need. Its global headquarters is in Wilmington, Delaware, United States, and the company maintains operations across North America, Europe, and Asia. Incyte was founded in 1991 and went public in 1993. It initially built its reputation in genomics and drug discovery before evolving into a more fully integrated therapeutics company with a core focus on oncology, hematology, and inflammation/autoimmunity. ([investor.incyte.com](https://investor.incyte.com/resources/investor-faqs?utm_source=openai)) From an investor perspective, Incyte is best viewed as a specialty biotech with a combination of marketed products and a substantial clinical pipeline. The company’s commercial portfolio includes Jakafi/Jakavi (ruxolitinib), a well-established therapy in certain myeloproliferative disorders; Opzelura (ruxolitinib cream), which gives Incyte a dermatology franchise; and Zynyz (retifanlimab), its immuno-oncology asset. Incyte also commercializes tafasitamab through Monjuvi in the United States and Minjuvi internationally, strengthening its position in hematology and lymphoma. ([incyte.com](https://incyte.com/?utm_source=openai)) Competitively, Incyte stands out by combining a meaningful commercial base with a research engine aimed at differentiated, mechanism-driven medicines. That matters in the highly competitive biotech sector, where execution on late-stage development and regulatory approvals can determine long-term value creation. The company’s strategy is to target diseases where clinical need remains significant and where its scientific expertise can support premium, specialty-market positioning. At the same time, investors should recognize that revenue remains concentrated in a limited number of key franchises, which is common in biotech but still a factor to monitor. ([incyte.com](https://incyte.com/?utm_source=openai)) Geographically, Incyte has a strong U.S. base but a genuinely international footprint, with commercial and development activities extending into Europe and Asia. Recent company highlights include new 2025 clinical data for Opzelura, povorcitinib in hidradenitis suppurativa, INCA033989 in myelofibrosis, and other pipeline assets such as bispecific and KRAS-focused programs. In late 2025 and early 2026, Incyte also reported or advanced multiple regulatory milestones for Zynyz and Minjuvi, underscoring a dense stream of clinical, regulatory, and commercial catalysts. For investors following SEC Form 4 insider activity, the company’s profile on the NYSE/NASDAQ universe is that of a U.S.-listed biotech with recurring commercial revenues and a catalyst-rich development portfolio. ([investor.incyte.com](https://investor.incyte.com/news-releases/news-release-details/incyte-announces-new-data-phase-3b-true-ad4-trial-opzelurar?utm_source=openai))